ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

• Understand the vicious cycle of COPD lung function decline and the current unmet need, specifically in patients with underlying type 2 inflammation​
• Describe the mechanistic pathways of type 2 inflammation in COPD, including the roles of key cytokines, and understand how these pathways contribute to lung function decline and negatively impact patients’ quality of life​
• Communicate recent Phase 3 clinical trial data for COPD biologics to understand which patients may benefit most from these therapies

Join leading pulmonologists Drs. Nicola Hanania, Surya Bhatt, and Celeste Porsbjerg, along with Sanofi and Regeneron, as they explore the burden of COPD in patients with underlying type 2 inflammation, delve into the mechanistic pathways driven by key cytokines contributing to lung function decline and reduced quality of life, and examine the latest Phase 3 clinical trial data to identify which patients may benefit most from emerging biologic therapies.